Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Marginal structural models as a tool for standardization.
Sato T, Matsuyama Y.
Epidemiology. 2003 Nov;14(6):680-6.
Similar articles
Marginal structural models and causal inference in epidemiology.
Robins JM, Hernán MA, Brumback B.
Epidemiology. 2000 Sep;11(5):550-60.
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.
Hernán MA, Brumback B, Robins JM.
Epidemiology. 2000 Sep;11(5):561-70.
Brief Report: Doubly Robust Estimation of Standardized Risk Difference and Ratio in the Exposed Population.
Shinozaki T, Matsuyama Y.
Epidemiology. 2015 Nov;26(6):873-7. doi: 10.1097/EDE.0000000000000363.
Differences between marginal structural models and conventional models in their exposure effect estimates: a systematic review.
Suarez D, Borràs R, Basagaña X.
Epidemiology. 2011 Jul;22(4):586-8. doi: 10.1097/EDE.0b013e31821d0507. Review.
Estimating causal parameters without target populations.
Shahar E.
J Eval Clin Pract. 2007 Oct;13(5):814-6.
Bounds on potential risks and causal risk differences under assumptions about confounding parameters.
Chiba Y, Sato T, Greenland S.
Stat Med. 2007 Dec 10;26(28):5125-35.
Analysis of longitudinal marginal structural models.
Bryan J, Yu Z, Van Der Laan MJ.
Biostatistics. 2004 Jul;5(3):361-80.
Marginal structural models for partial exposure regimes.
Vansteelandt S, Mertens K, Suetens C, Goetghebeur E.
Biostatistics. 2009 Jan;10(1):46-59. doi: 10.1093/biostatistics/kxn012. Epub 2008 May 23.
Marginal structural models might overcome confounding when analyzing multiple treatment effects in observational studies.
Suarez D, Haro JM, Novick D, Ochoa S.
J Clin Epidemiol. 2008 Jun;61(6):525-30. doi: 10.1016/j.jclinepi.2007.11.007. Review.
Bounding causal effects under uncontrolled confounding using counterfactuals.
MacLehose RF, Kaufman S, Kaufman JS, Poole C.
Epidemiology. 2005 Jul;16(4):548-55. Review.
Invited commentary: G-computation--lost in translation?
Vansteelandt S, Keiding N.
Am J Epidemiol. 2011 Apr 1;173(7):739-42. doi: 10.1093/aje/kwq474. Epub 2011 Mar 16.
Use of tamoxifen in pT1a-pT1b, pN0 breast cancer.
Livi L, Saieva C, Paiar F, Simontacchi G, Galardi A, De Luca Cardillo C, Mangoni M, Paoletti L, Ponticelli P, Biti GP.
Eur J Surg Oncol. 2007 Apr;33(3):271-5. Epub 2006 Jul 10.
Acceptance of tamoxifen chemoprevention by physicians and women at risk.
Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M.
Cancer. 2004 May 1;100(9):1800-6.
Marginal mean weighting through stratification: a generalized method for evaluating multivalued and multiple treatments with nonexperimental data.
Hong G.
Psychol Methods. 2012 Mar;17(1):44-60. doi: 10.1037/a0024918. Epub 2011 Aug 15.
Marginal structural models: much ado about (almost) nothing.
Shahar E, Shahar DJ.
J Eval Clin Pract. 2013 Feb;19(1):214-22. doi: 10.1111/j.1365-2753.2011.01757.x. Epub 2011 Aug 23.
Nonparametric estimation of the bivariate recurrence time distribution.
Huang CY, Wang MC.
Biometrics. 2005 Jun;61(2):392-402.
Fitting marginal structural models: estimating covariate-treatment associations in the reweighted data set can guide model fitting.
Pullenayegum EM, Lam C, Manlhiot C, Feldman BM.
J Clin Epidemiol. 2008 Sep;61(9):875-81. doi: 10.1016/j.jclinepi.2007.10.024. Epub 2008 May 16.
Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology.
Bodnar LM, Davidian M, Siega-Riz AM, Tsiatis AA.
Am J Epidemiol. 2004 May 15;159(10):926-34.
Marginal structural models for the estimation of direct and indirect effects.
VanderWeele TJ.
Epidemiology. 2009 Jan;20(1):18-26. doi: 10.1097/EDE.0b013e31818f69ce. Erratum in: Epidemiology. 2009 Jul;20(4):629.
Filters: Manage Filters